GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » MDxHealth SA (NAS:MDXH) » Definitions » Total Liabilities

MDXH (MDxHealth) Total Liabilities : $142.49 Mil (As of Dec. 2024)


View and export this data going back to 2008. Start your Free Trial

What is MDxHealth Total Liabilities?

MDxHealth's Total Liabilities for the quarter that ended in Dec. 2024 was $142.49 Mil.

MDxHealth's quarterly Total Liabilities increased from Jun. 2024 ($139.67 Mil) to Sep. 2024 ($140.41 Mil) and increased from Sep. 2024 ($140.41 Mil) to Dec. 2024 ($142.49 Mil).

MDxHealth's annual Total Liabilities increased from Dec. 2022 ($109.82 Mil) to Dec. 2023 ($121.92 Mil) and increased from Dec. 2023 ($121.92 Mil) to Dec. 2024 ($142.49 Mil).


MDxHealth Total Liabilities Historical Data

The historical data trend for MDxHealth's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MDxHealth Total Liabilities Chart

MDxHealth Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.01 28.17 109.82 121.92 142.49

MDxHealth Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.92 - 139.67 140.41 142.49

MDxHealth Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MDxHealth's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=42.663+(58.38+41.445
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=142.49

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=157.329-14.841
=142.49

MDxHealth's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=42.663+(58.38+41.445
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=142.49

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=157.329-14.841
=142.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MDxHealth Total Liabilities Related Terms

Thank you for viewing the detailed overview of MDxHealth's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


MDxHealth Business Description

Traded in Other Exchanges
N/A
Address
Zone Industrielle des Hauts-Sarts, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.